National Fellows Forum

A program specifically designed to support the professional development of oncology fellows.
Through expert-led panel discussions, presentation opportunities, and peer-to-peer engagement, fellows gain insights that bridge academic training and clinical decision-making.
Fosters a collaborative learning environment that empowers the next generation of oncology leaders.

Events

National Fellows Forum: Breast Cancer

Upcoming Event

National Fellows Forum: Breast Cancer

December 9, 2026 · 900 E. Market Street, San Antonio, TX 78205

National Fellows Forum: Hematology

Upcoming Event

National Fellows Forum: Hematology

December 11, 2026 · New Orleans, Louisiana

Lung Cancer

Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center.

First-in-Human: Jyoti Malhotra, MD, MPH on Phase I Trials, Lung Cancer in 2026, and Yale

Dr William on First-Line EGFR-Mutant NSCLC in AMIGO-1

Dr William on First-Line EGFR-Mutant NSCLC in AMIGO-1

Dr Rotow on Osimertinib Plus Gefitinib for First-Line EGFR-Mutant NSCLC

Dr Rotow on Osimertinib Plus Gefitinib for First-Line EGFR-Mutant NSCLC

Dr Alder on Time-of-Day Impact on Tarlatamab Infusions for SCLC

Dr Alder on Time-of-Day Impact on Tarlatamab Infusions for SCLC

Dr Alder on Treatment Beyond Progression With Tarlatamab in SCLC

Dr Alder on Treatment Beyond Progression With Tarlatamab in SCLC

Dr Rotow on the Updated Treatment Cadence for HER2-Mutant NSCLC

Dr Rotow on the Updated Treatment Cadence for HER2-Mutant NSCLC

Dr Rotow on DESTINY-Lung04 Outcomes at WCLC 2026

Dr Rotow on DESTINY-Lung04 Outcomes at WCLC 2026

ARROS-1 in ROS1+ NSCLC | Image Credit: © Ashling Wahner & MJH Life Sciences Using AI

Dr Drilon on How the ARROS-1 Trial May Affect the Current Paradigm in ROS1+ NSCLC

Zidesamtinib in ROS1+ NSCLC | Image Credit: © Ashling Wahner & MJH Life Sciences Using AI

Dr Drilon on the ARROS-1 Trial Data With Zidesamtinib in ROS1+ NSCLC

Dr Gandara on Expanding Beyond PD-L1 as a Biomarker in NSCLC

Dr Gandara on Expanding Beyond PD-L1 as a Biomarker in NSCLC

Genitourinary Cancers

Adanma Ayanambakkam, MD, MS

Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD

Adanma Ayanambakkam, MD, MS,

Dr Ayanambakkam on the Design of the FIT-001 Trial in Renal Cell Carcinoma

Adanma Ayanambakkam, MD, MS

Dr Ayanambakkam on the FIT-001 Study in Renal Cell Carcinoma

Toni Choueiri, MD, Dana-Farber Cancer Institute

Dr Choueiri on Safety Data From the Phase 3 LITESPARK-022 Trial in ccRCC

Toni Choueiri, MD, Dana-Farber Cancer Institute

Dr Choueiri on the Phase 3 LITESPARK-022 Trial of Belzutifan Plus Pembrolizumab in ccRCC

Toni Choueiri, MD, Dana-Farber Cancer Institute

Dr Choueiri on Integrating Adjuvant Belzutifan Plus Pembrolizumab into Clinical Practice in RCC

Toni Choueiri, MD, Dana-Farber Cancer Institute

Dr Choueiri on the FDA Approval of Adjuvant Belzutifan Plus Pembrolizumab in ccRCC

Benjamin Croll, MD, Fox Chase Cancer Center

Dr Croll on the Development of Biomarkers in RCC

Benjamin Croll, MD, Fox Chase Cancer Center

Dr Croll on Understanding Tumor Response to Systemic Therapy in RCC

Benjamin Croll, MD, Fox Chase Cancer Center

Dr Croll on Radiographic Size Change vs irRVT After Neoadjuvant Therapy in RCC

Oncology Fellows